Solid Biosciences
NASDAQ: SLDBCharlestown, US · Delaware corporation · 3 known investors
Solid Biosciences is a precision genetic medicine company developing a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, CPVT, and TNNT2-mediated dilated cardiomyopathy. It also develops genetic regulator libraries and delivery platform technologies intended to improve gene therapy delivery.
BiotechHealthtech
Founders & leadership
SD
Stephen DiPalmaExecutive
A(
Alexander (Bo) CumboExecutive
CM
Carl MorrisExecutive
MF
Martin FreedNamed on SEC filing
PH
Paul HerizchNamed on SEC filing
RH
Robert HuffinesNamed on SEC filing
Board
AK
AS
Adam StoneBoard director
RS
LS
Lynne SullivanBoard director
CK
Clare KahnBoard director
GK
Georgia KerestyBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$109.2M disclosed across 3 rounds · 2019–2022
▶$9.2MraisedDec 2022 · 13 investors · PharmaceuticalsRule 506(b)
▶$9.2MraisedDec 2022 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Lynne SullivanDirector
- Adam KoppelDirector
- Stephen DiPalmaExecutive Officer
- Martin FreedDirector
- Alexander (Bo) CumboExecutive Officer, Director
- Paul HerizchExecutive Officer
- Clare KahnDirector
- Georgia KerestyDirector
- Adam StoneDirector
- Rajeev ShahDirector
- Robert HuffinesDirector
- Carl MorrisExecutive Officer
- Jessie HanrahanExecutive Officer
- Sukumar NagendranDirector
- Ilan GanotDirector
- David Tyronne HowtonExecutive Officer
- Jennifer MarloweExecutive Officer
- Ian SmithDirector
- Offering amount
- $9.2M
- Amount sold
- $9.2M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$40MraisedOct 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$40MraisedOct 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ian SmithDirector
- Martin FreedDirector
- Lynne SullivanDirector
- Adam StoneDirector
- Matthew ArnoldDirector
- Rajeev ShahDirector
- Sukumar NagendranDirector
- Adam KoppelDirector
- Robert HuffinesDirector
- Joel SchneiderExecutive Officer
- Carl MorrisExecutive Officer
- Lynette HerschaExecutive Officer
- Ilan GanotExecutive Officer, Director
- Jennifer ZiolkowskiExecutive Officer
- Offering amount
- $40M
- Amount sold
- $40M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$60MraisedJul 2019 · 15 investors · PharmaceuticalsRule 506(b)
▶$60MraisedJul 2019 · 15 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Carl MorrisExecutive Officer
- Martin FreedDirector
- Lynne SullivanDirector
- Ilan GanotExecutive Officer, Director
- Alvaro AmorrortuExecutive Officer
- Lynette HerschaExecutive Officer
- Andrey ZarurDirector
- Joel SchneiderExecutive Officer
- Jorge A. QuirozExecutive Officer
- Jennifer ZiolkowskiExecutive Officer
- Robert HuffinesDirector
- Adam KoppelDirector
- Sukumar NagendranDirector
- Rajeev ShahDirector
- Matthew ArnoldDirector
- Adam StoneDirector
- Offering amount
- $60M
- Amount sold
- $60M
- Sales commissions
- $1.8M
- Placement agents
- SVB Leerink LLC
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapSeeking Alpha34 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.
TipRanks26 shared keywordsFinancial analysis and stock research platform.
Companies competing with Solid Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Solid Biosciences do?
- Solid Biosciences is a precision genetic medicine company developing a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, CPVT, and TNNT2-mediated dilated cardiomyopathy. It also develops genetic regulator libraries and delivery platform technologies intended to improve gene therapy delivery.
- Who are Solid Biosciences's investors?
- Solid Biosciences's investors include Bain Capital Life Sciences, Foresite Capital, RA Capital.
- How much funding has Solid Biosciences raised?
- Solid Biosciences has disclosed $109.2M raised across 3 rounds.
- Where is Solid Biosciences headquartered?
- Solid Biosciences is headquartered in Charlestown, US.